TESARO Newswire

TESARO Newswire

Comprehensive Real-Time News Feed for TESARO.

Results 1 - 20 of 52 in TESARO

  1. Analysts Expect TESARO Inc (TSRO) Will Announce Quarterly Sales of $51.73 MillionRead the original story w/Photo

    Jan 2, 2018 | AmericanBankingNews.com

    Wall Street brokerages expect that TESARO Inc will report $51.73 million in sales for the current quarter, Zacks Investment Research reports. Eight analysts have made estimates for TESARO's earnings, with estimates ranging from $46.07 million to $59.17 million.

    Comment?

  2. New York State Common Retirement Fund Buys 3,000 Shares of TESARO IncRead the original story w/Photo

    Dec 18, 2017 | IntersportsWire

    New York State Common Retirement Fund grew its stake in shares of TESARO Inc by 2.9% in the third quarter, according to its most recent filing with the SEC. The fund owned 107,497 shares of the biopharmaceutical company's stock after acquiring an additional 3,000 shares during the period.

    Comment?

  3. Insider Selling: TESARO Inc (TSRO) SVP Sells 829 Shares of StockRead the original story w/Photo

    Dec 5, 2017 | AmericanBankingNews.com

    TESARO Inc SVP Martin H. Jr. Huber sold 829 shares of the business's stock in a transaction on Monday, December 4th. The stock was sold at an average price of $85.24, for a total value of $70,663.96.

    Comment?

  4. Crossmark Global Holdings Inc. Buys Shares of 1,785 TESARO IncRead the original story w/Photo

    Dec 3, 2017 | Daily Political

    Crossmark Global Holdings Inc. bought a new position in TESARO Inc during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 1,785 shares of the biopharmaceutical company's stock, valued at approximately $230,000.

    Comment?

  5. TESARO (TSRO) Given a $154.00 Price Target by Argus AnalystsRead the original story w/Photo

    Nov 29, 2017 | The Breeze

    ... on TSRO. Robert W. Baird reiterated a neutral rating and set a $140.00 price target (down from $155.00) on shares of TESARO in a research report on Thursday, August 10th. HC Wainwright reiterated a buy rating and set a $158.00 price target on shares ...

    Comment?

  6. Bank of New York Mellon Corp Has $73.57 Million Stake in TESARO IncRead the original story w/Photo

    Nov 29, 2017 | IntersportsWire

    Bank of New York Mellon Corp decreased its holdings in shares of TESARO Inc by 19.0% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 569,856 shares of the biopharmaceutical company's stock after selling 133,918 shares during the quarter.

    Comment?

  7. The one thing the best entrepreneurs have in commonRead the original story w/Photo

    Nov 23, 2017 | USA Today

    ... the Life Sciences division, Lonnie Moulder and Mary Lynne Hedley started and run a pharmaceutical business called TESARO. Their mission? Nothing less than finding cure for, and wiping out, ovarian cancer. (The name TESARO comes from the Galician ...

    Comment?

  8. TESARO, Inc. to Post FY2017 Earnings ofRead the original story w/Photo

    Nov 17, 2017 | AmericanBankingNews.com

    Research analysts at Leerink Swann raised their FY2017 EPS estimates for shares of TESARO in a research note issued to investors on Wednesday. Leerink Swann analyst S. Fernandez now anticipates that the biopharmaceutical company will post earnings per share of for the year, up from their prior estimate of .

    Comment?

  9. Cann Reiterates Buy Rating for TESARO, Inc.Read the original story w/Photo

    Nov 9, 2017 | IntersportsWire

    ... than estimated R&D expense. Due to the combination of higher than estimated revenue and slightly lower expenses, Tesaro lost $0.47 per share compared to our estimated loss per share of $2.56."" Several other research firms have also recently weighed ...

    Comment?

  10. TESARO, Inc. (TSRO) Earns Buy Rating from HC WainwrightRead the original story w/Photo

    Nov 8, 2017 | AmericanBankingNews.com

    ... to investors on Wednesday. TSRO has been the topic of a number of other research reports. BidaskClub downgraded TESARO from a "sell" rating to a "strong sell" rating in a report on Wednesday, July 19th. Wedbush reiterated an "outperform" rating and ...

    Comment?

  11. TESARO, Inc. (TSRO) Earns "Buy" Rating from CannRead the original story w/Photo

    Nov 7, 2017 | Daily Political

    ... than estimated R&D expense. Due to the combination of higher than estimated revenue and slightly lower expenses, Tesaro lost $0.47 per share compared to our estimated loss per share of $2.56."" Other research analysts have also issued reports about ...

    Comment?

  12. TESARO, Inc. (TSRO) Rating Reiterated by Jefferies Group LLCRead the original story w/Photo

    Nov 5, 2017 | AmericanBankingNews.com

    ... of 11.80% from the stock's previous close. TSRO has been the topic of a number of other reports. BidaskClub lowered TESARO from a "sell" rating to a "strong sell" rating in a research report on Wednesday, July 19th. Wedbush reaffirmed an ...

    Comment?

  13. AnaptysBio to Participate in Upcoming Investor ConferencesRead the original story

    Oct 31, 2017 | Customer Interaction Solutions

    ... technologies. AnaptysBio has also developed multiple therapeutic antibodies in an immuno-oncology partnership with TESARO and an inflammation partnership with Celgene, including an anti-PD-1 antagonist antibody (TSR-042), an anti-TIM-3 antagonist ...

    Comment?

  14. AnaptysBio to Participate in Upcoming Investor ConferencesRead the original story w/Photo

    Oct 31, 2017 | GlobeNewswire

    ... technologies. AnaptysBio has also developed multiple therapeutic antibodies in an immuno-oncology partnership with TESARO and an inflammation partnership with Celgene, including an anti-PD-1 antagonist antibody (TSR-042), an anti-TIM-3 antagonist ...

    Comment?

  15. Tesaro Announces U.S. FDA Approval of Varubi IV for Delayed Nausea...Read the original story w/Photo

    Oct 24, 2017 | Drugs.com

    Tesaro, Inc. , an oncology-focused biopharmaceutical company, today announced that the U.S. Food and Drug Administration has approved Varubi IV in combination with other antiemetic agents in adults for the prevention of delayed nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy, including, but not limited to, highly emetogenic chemotherapy. Delayed nausea and vomiting can occur anytime between 25 and 120 hours following chemotherapy, and is often extremely debilitating.

    Comment?

  16. Evotec and TESARO Enter Strategic Partnership to Discover Novel Immuno-Oncology AgentsRead the original story

    Oct 26, 2017 | Customer Interaction Solutions

    Evotec AG and TESARO, Inc. today announced a three-year integrated drug discovery collaboration to discover and develop novel small molecule product candidates against an undisclosed immuno-oncology target. Under the terms of the collaboration, Evotec will apply its integrated drug discovery platform, from lead discovery through nomination of a pre-clinical development candidate, to TESARO's translational research pipeline to advance best-in-class oncology therapies.

    Comment?

  17. The Inaugural Europe CEO Takes Place on November 14 to Bring Together...Read the original story

    Oct 25, 2017 | PRWeb

    "The insights gleaned from the panels and presentations, and connections made with industry peers, make this a must-attend event." - Lonnie Moulder, Co-Founder & CEO, TESARO For the first time, Boston Biotech Conferences is hosting Europe CEO on November 14, 2017 at the Four Seasons Hotel at Park Lane in London.

    Comment?

  18. TESARO Announces Participation at Two Investor ConferencesRead the original story w/Photo

    Oct 23, 2017 | GlobeNewswire

    WALTHAM, Mass., Oct. 23, 2017 -- TESARO, Inc. , an oncology-focused biopharmaceutical company, today announced its participation in two upcoming investor conferences. The two conferences are: The Credit Suisse 26th Annual Healthcare Conference at The Phoenician in Scottsdale, Arizona on Monday, November 6 and Tuesday, November 7. Lonnie Moulder, CEO of TESARO, and Mary Lynne Hedley, Ph.D., President and COO of TESARO, are scheduled to participate in an analyst-led fireside chat at 10:55 AM MT on Tuesday, November 7, and will also host meetings with investors.

    Comment?

  19. 4 Biotech Stocks Initiated At Buy: Acceleron, Tesaro, Mirati, FateRead the original story w/Photo

    Oct 12, 2017 | Benzinga

    ... respectively, in 2026," White wrote. H.C. Wainwright has a $20 price target for Mirati stock. White said TESARO Inc (NASDAQ: TSRO ) isn't getting enough credit for its U.S. Zejula launch and the rest of its impressive pipeline. He expects 2018 ...

    Comment?

  20. -$1.19 EPS Expected for TESARO, Inc. (TSRO) This QuarterRead the original story w/Photo

    Oct 1, 2017 | AmericanBankingNews.com

    Equities research analysts forecast that TESARO, Inc. will report earnings per share of for the current quarter, according to Zacks . Seven analysts have provided estimates for TESARO's earnings.

    Comment?